Medigene Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Press Release: Medigene expands end-to-end technology platform through worldwide, exclusive license of a CD40L-CD28 Costimulatory Switch Receptor further enhancing potential to treat solid tumors
Medigene accelerates the expansion of its end-to-end platform of multiple, combinable, exclusive and proprietary technologies with the potential to create best-in-class T cell receptor engineered T. | May 2, 2023
MDG1011 was generally well tolerated in nine heavily pre-treated patients across three ascending dose levelsNo neurotoxicity or dose-limiting toxicities observedTwo out of nine patients showed early. | June 18, 2023